Butylphthalide + Butylphthalide placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
ST-segment Elevation Myocardial Infarction (STEMI)
Conditions
ST-segment Elevation Myocardial Infarction (STEMI)
Trial Timeline
Dec 1, 2024 → Dec 31, 2025
NCT ID
NCT06704685About Butylphthalide + Butylphthalide placebo
Butylphthalide + Butylphthalide placebo is a phase 3 stage product being developed by CSPC Pharmaceutical Group Limited for ST-segment Elevation Myocardial Infarction (STEMI). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06704685. Target conditions include ST-segment Elevation Myocardial Infarction (STEMI).
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06704685 | Phase 3 | Recruiting |
Competing Products
1 competing product in ST-segment Elevation Myocardial Infarction (STEMI)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel) | Shenzhen Salubris Pharmaceuticals | Pre-clinical | 22 |
Other Products from CSPC Pharmaceutical Group Limited
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenPhase 2
51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsPhase 2
51
Sintilimab + Nab paclitaxel + CisplatinPhase 2
51
pegylated liposomal doxorubicin (PLD) + PD-1Phase 2
51
liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + BevacizumabPhase 1/2
40